Advancements In Car T-Cells To Better Tackle Peripheral T-Cell Lymphomas Market Outlook: Ken Research

According to the study, ‘PERIPHERAL T-CELL LYMPHOMAS (PTCL) GLOBAL CLINICAL TRIALS REVIEW, H1, 2018’, cancer treatment around the world is improving rapidly and lymphatic cancer is no exception despite the exact causes of peripheral T-cell lymphoma being currently unknown. However, the cancer is believed to be associated with the exposure to viruses such as the human T-cell leukemia virus-1 (HTLV-1). Presently available treatment includes chemotherapy, localized radiotherapy, stem cell transplants and steroid therapy. New treatment options are also being explored and experimented. Understanding the causes of PTCL has been a major contributor to this new development.    

Lymphoma is a cancer of the lymphatic system which affects a type of white blood cell known as lymphocytes that help fight diseases in the body.    T-cell is a type of white blood cell that is of key importance to the immune system that triggers the body’s response to certain pathogens. A similar lymphocyte called Natural Killer (NK) cell shares many features with T-cells. When NK cells become cancerous, the cancer is called NK or T-cell lymphoma and develops in lymphoid tissue such as the lymph nodes and spleen. Peripheral T-cell lymphoma (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature stage white blood cells called T-cells and NK cells.

In May 2018, the American Society of Clinical Oncology (ASCO) announced chimeric antigen receptor (CAR) T-cell therapy as Advance of The Year for 2018. CAR T-cell therapy is a type of treatment in which a patient’s T-cells are changed in the laboratory such that they will attack cancer cells. T-cells are taken from a patient’s blood and then the gene for a special receptor that binds to the CD-19 protein on the cancer cells is added in the laboratory.  This special receptor is called CAR. Large numbers of CAR T-cells are grown in the laboratory and are given to the patient by infusion.

In 2017 also there were major triumphs for this technology as the year saw some major developments regarding the same. Two CAR T-cell therapies were approved by the US FDA, one for the treatment of children with acute lymphoblastic leukemia and the other for adults with advanced lymphomas. These clinical successes are part of a rapidly emerging immunotherapy approach which is called adoptive cell transfer (ACT) which is collecting and altering the patient’s own immune cells to treat their cancer. There are several types of ACT but the one that has advanced the furthest in clinical development is CAR T-cell therapy.

 This approach is currently being seen as a means to transform cancer care as it represents an exciting innovation. CAR T-cell therapy is clinically the most advanced of the adoptive cell transfer (ACT) class of immunotherapy and has primarily been used in patients with advanced blood cancer. Nevertheless, researchers are still developing the field of ACT in order to expand their effectiveness against solid tumors such as breast and colorectal cancer. Immunotherapy is continuously innovating and developments like CAR T-cells cement this fact with present operative capacity in lymphatic sectors. Many more CAR T-cell clinical trials are currently underway and further substantial progress is expected in the next few years.

To know more, click on the link below:

https://www.kenresearch.com/healthcare/general-healthcare/peripheral-t-cell-lymphomas/150994-91.html

Related Reports

https://www.kenresearch.com/healthcare/pharmaceuticals/peripheral-t-cell-lymphomas-ptcl-global-clinical-trials-review-h2-2016/54153-91.html

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
sales@kenresearch.com

+91-9015378249

Modernization and Stringent Environment Norms to Drive Activated Carbon Fiber Market in Asia-Ken Research

Activated carbon fiber cloth is a synthetic alternative adsorbent which is a conventional granular activated carbon used for capture and recovery of volatile organic substances from gas streams. Activated carbon fiber cloth has up to twice the adsorption capacity of typical granular carbon and is more suitable to electrothermal regeneration. Activated charcoal fibers are manufactured using rayon technical filament yarn, possess effective absorption, high-efficient absorption for low-concentrated solutions, easy to use, and easy to recover. They possess large specific surface areas, more adsorption area, reduces pressure losses and many more uses. Activated charcoal fibers are used as filters for organic substances when substance concentration level is low, for regeneration of organic solvents, galvanic grouts purification, oil-separators for sewage water at gas stations and car cleaning stations, air-cleaners / odour-absorbers, used as super-capacitors, as water purification filters, filtering material for protective clothes, gas-masks for contact with toxic substances or poisons, welding gas filtration, smoking room filter, cigarette filter, filtration or purification of vodka and other strong beverages.

According to the study “Asia Activated Charcoal Fiber Industry Situation and Prospects Research Report”, activated carbon fibers are used as alternative adsorbent materials with thinners, light-weight, and efficient respirators because of their larger surface area, lighter weight, and fabric form. Activated carbon fibers are majorly used in respiratory protection against toluene in various toluene industries. Therefore, more thinner and efficient respirators are manufactured using activated carbon fibers. Activated charcoal fibers are widely used in many industries due to their great adsorption properties and desirable physical properties, such as high mechanical strength, thermal resistance, light weight, and safety profile. The industrial and commercial uses include water treatment, gas masks and equipment for removal of toxic gases.

Various applications of activated charcoal fibers are in solvent recovery, air purification, water treatment, catalyst carrier and others. Various products in Asia’s activated charcoal fiber are pitch based activated carbon fiber, polyacrylonitrile (pan) based activated carbon fiber and viscose staple based activated carbon fiber. Activated charcoal fiber in Asia market is geographically spread across China, Japan, India, Korea, Saudi Arabia and other regions. The leading manufacturers of Activated charcoal fiber in Asia market are Toyobo, Kuraray, Unitika, Gunei Chem, Evertech Envisafe Ecology, Taiwan Carbon Technology, Awa Paper, HP Materials Solutions, Sutong Carbon Fiber, Jiangsu Tongkang, Anhui Jialiqi, Nantong Senyou, Kejing Carbon Fiber, Nantong Beierge, Nantong Yongtong, Xintong ACF, Nature Technology, Hailan Filtration Tech, Sinocarb Carbon Fibers, Nantong Jinheng and Zichuan Carbon Fiber. Majority of the manufacturers are investing heavily in research and development to improve their products. The leading vendors are focusing on creating strong brand names, offering well-established products, and exhibit long-term reliability. The vendors are increasingly competing against each other based on factors such as price, features, and product quality.

Water treatment is the largest application of activated charcoal fibers because it is used in municipal wastewater treatment and other industrial processes. It is used in the treatment of water in aquariums, groundwater remediation, and potable water. To meet the stringent industrial process requirements of water in beverage production, energy and life sciences, activated charcoal fibers are used. Mercury emission in Asian countries is increasing due to the rising electric production in countries such as China and India. The stringent environmental regulations due to increasing automobiles in the developing and developed countries will witness a steady growth in activated charcoal fibers market over the next few years.

To know more, click on the link below:

https://www.kenresearch.com/metal-mining-and-chemicals/chemicals/asia-activated-charcoal-fiber-industry-situation-and-prospects-research-report/145765-101.html

Related Reports:

https://www.kenresearch.com/metal-mining-and-chemicals/chemicals/north-america-activated-charcoal-fiber-industry-situation-and-prospects-research-report/146443-101.html

https://www.kenresearch.com/metal-mining-and-chemicals/chemicals/china-activated-charcoal-fiber-industry-situation-and-prospects-research-report/146275-101.html

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249

Menopausal Disorders Drug Development Research Report : Ken Research

Menopausal Disorders Drug Development Research Report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for postmenopausal osteoporosis, vaginal atrophy and vasomotor symptoms of menopause, and features dormant and discontinued products.

Postmenopausal osteoporosis is the most common form of osteoporosis. It affects many women after menopause. Symptoms include back pain, loss of height, or spinal deformities such as stooped posture. Risk factors include age, gender, family history, bone structure and body weight. There are 20 products in development for this indication.

Vaginal atrophy is thinning, drying and inflammation of the vaginal walls due to the body having less estrogen. Signs and symptoms include vaginal dryness, vaginal discharge, genital itching, burning with urination, and urgency with urination, urinary tract infections and urinary incontinence.

Risk factor includes smoking. Smoking impairs blood circulation, depriving the vagina and other tissues of oxygen. Tissue thinning occurs where blood flow is decreased or restricted. There are five products in development for this indication.

Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders. There are 12 products in development for this indication.

Molecular targets acted on by products in development for menopausal disorders include tumor necrosis factor ligand superfamily member 11, parathyroid hormone receptor and progesterone receptor. Companies operating in this pipeline space include Amgen, TherapeuticsMD and Ipsen.

The report also includes the following details:-

- Which companies are the most active within each pipeline?

- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?

- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

- What are the most important R&D milestones and data publications to have happened in this disease area?

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each

- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these

- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

To know more, click on the link below:

https://www.kenresearch.com/healthcare/pharmaceuticals/menopausal-disorders/149725-91.html

Contact Us:

Ken Research

Ankur Gupta, Head Marketing & Communications

sales@kenresearch.com

+91-9015378249